z-logo
Premium
The Duffy antigen receptor for chemokines, ACKR 1 ,– ‘Jeanne DARC ’ of benign neutropenia
Author(s) -
Rappoport Naama,
Simon Amos J.,
Amariglio Ninette,
Rechavi Gideon
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15730
Subject(s) - immunology , neutropenia , biology , allele , chemokine , null allele , receptor , inflammation , gene , genetics , chemotherapy
Summary Benign neutropenia, observed in different ethnic groups, is the most common form of neutropenia worldwide. A specific single nucleotide polymorphism, rs2814778 , located at the promoter of the ACKR 1 (previously termed DARC ) gene, which disrupts a binding site for the GATA 1 erythroid transcription factor, resulting in a ACKR 1 ‐null phenotype, was found to serve as a predictor of low white blood cell and neutrophil counts in African‐Americans and Yemenite Jews. Individuals with benign neutropenia due to the ACKR 1 ‐null allele have been found to have an increased susceptibility to human immunodeficiency virus infection and, on the other hand, a protective effect against malaria. The associated protective effect may explain the spread of the ACKR 1 ‐null allele by natural selection. The reviewed relationships between ACKR 1 polymorphism and various pathological states may have important clinical implications to individuals with and without benign neutropenia. Potential mechanisms for ACKR 1 (previously termed DARC ) modulation during neutrophil recruitment to inflammation, and chemokine bioavailability in the circulation and in local tissue are reviewed and discussed.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here